Amarin | AMRN - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
AbbVie USD 12.54B 474M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
AstraZeneca USD 12.61B 225M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12